Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
About Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company headquartered in Oviedo, Florida, specializing in the development and commercialization of innovative transdermal drug delivery systems. The company’s primary focus lies in leveraging its proprietary AVERSA™ abuse-deterrent technology to address critical safety concerns in the pharmaceutical industry, particularly related to opioid medications. By integrating aversive agents into transdermal patches, Nutriband enhances safety by preventing the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Technology
Nutriband’s flagship product under development is the AVERSA™ Fentanyl transdermal patch, which aims to become the world’s first abuse-deterrent opioid patch. This innovative technology incorporates aversive agents, such as denatonium benzoate (Bitrex®), to create a bitter taste that deters oral abuse and accidental exposure, particularly in children. The AVERSA™ platform technology is versatile and can be applied to other transdermal formulations, broadening its potential applications in the pharmaceutical market.
The company operates within a robust intellectual property framework, with patents granted in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This extensive portfolio underscores Nutriband’s commitment to securing its technological innovations on a global scale.
Revenue Streams and Market Reach
Nutriband generates revenue through multiple channels, including the sale of consumer transdermal and coated products, as well as contract manufacturing services provided by its subsidiary, Pocono Pharma. Pocono Pharma specializes in kinesiology tape manufacturing and serves major retail clients, such as Target, Walmart, Walgreens, and CVS. This diversification not only strengthens Nutriband’s financial foundation but also positions it as a trusted partner in the manufacturing of specialized consumer healthcare products.
Industry Context and Competitive Position
Nutriband operates at the intersection of the pharmaceutical and healthcare industries, addressing critical challenges such as the opioid crisis and medication safety. The company’s AVERSA™ technology aligns with growing regulatory and societal demand for safer drug delivery systems. By focusing on transdermal solutions, Nutriband differentiates itself from competitors that primarily rely on traditional oral or injectable drug formulations. Its partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, further enhances its capabilities in scaling and commercializing its products.
Intellectual Property and Global Expansion
With patents issued in major global markets, Nutriband has established a strong foundation for international expansion. Recent advancements include the extension of its intellectual property to regions such as Hong Kong and Macao, further solidifying its presence in Asia. These developments position Nutriband as a leader in the abuse-deterrent pharmaceutical space, capable of addressing both regional and global market needs.
Commitment to Innovation and Patient Safety
At its core, Nutriband is driven by a mission to enhance patient safety through innovative technologies. The AVERSA™ platform not only addresses the risks associated with opioid misuse but also ensures that essential medications remain accessible to patients who need them. This dual focus on safety and accessibility underscores Nutriband’s role as a socially responsible player in the pharmaceutical industry.
Conclusion
In summary, Nutriband Inc. is a pioneering company in the field of transdermal drug delivery, leveraging its proprietary AVERSA™ technology to address pressing healthcare challenges. With a diversified revenue model, strong intellectual property portfolio, and strategic partnerships, Nutriband is well-positioned to make a meaningful impact in the pharmaceutical and healthcare industries.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has received approval from the Costa Rica Ministry of Health for its Mosquito Repellent Patch. The product, designed to reduce mosquito bites and associated health risks, will be exclusively distributed through Farmavision S.A. in Costa Rica. Nutriband plans to expand distribution throughout South and Central America.
The global mosquito repellent market is projected to reach USD $9.30 Billion by 2029 with a 5.23% annual growth rate. The patch contains natural ingredients to mask human odors attractive to insects. It's similar to patches approved in African countries like Ghana, Nigeria, and Ivory Coast for reducing malaria and HIV spread.
Nutriband's subsidiary, Pocono Pharmaceutical, will be the exclusive manufacturer of the product.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is hosting an exclusive live investor webinar and Q&A session on October 17, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature Nutriband Founder and CEO Gareth Sheridan and Founder and President Serguei Melnik, who will discuss the company's current operations and upcoming milestones.
Nutriband is addressing the global opioid crisis with its AVERSA™ abuse-deterrent transdermal technology. The company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway, requiring only a single Phase 1 trial with potential for an expedited six-month FDA review.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the Chinese National Intellectual Property Administration (CNIPA) for its patent application covering the AVERSA™ abuse deterrent transdermal technology. This technology incorporates aversive agents into transdermal patches to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulants.
The AVERSA™ technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. Nutriband is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the world's first abuse-deterrent opioid patch. This product could reach annual US sales of $80 million to $200 million.
The proprietary aversive agent coating employs taste aversion and has shown resistance to removal in preliminary studies. It also features a patented immediate and extended-release profile for additional deterrence.
Nutriband Inc. (NASDAQ:NTRB) has signed a trademark licensing agreement for Bitrex® brand denatonium benzoate, the world's most bitter substance, as an aversive agent in its lead product, AVERSA™ Fentanyl. This abuse-deterrent fentanyl patch incorporates Nutriband's proprietary technology to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
The AVERSA™ technology uses a taste aversion coating that is difficult to remove and has a patented immediate and extended-release profile. This additional layer of deterrence prevents easy separation of the drug from the aversive agents. Bitrex® is known for its extremely bitter taste, making products unpalatable and helping prevent accidental ingestion, especially in children.
Nutriband is collaborating with Kindeva Drug Delivery to develop the commercial scale manufacturing process. AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch, with estimated peak annual US sales of $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has authorized a $1 million share buyback program for its common stock. As of September 16, 2024, the company had 11,106,185 outstanding common shares. Nutriband is primarily focused on developing transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch incorporating the AVERSA™ abuse deterrence technology. The company maintains its target of submitting an NDA to the FDA in Q1/Q2 2025 for AVERSA Fentanyl. AVERSA™ technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc. (NASDAQ:NTRB) has released its Q2 2024 financial report, highlighting a strong cash position of $6.75 million and strategic progress towards its NDA filing for AVERSA Fentanyl in 2025. The company is expanding its kinesiology tape contract manufacturing through Pocono Pharma, targeting major retailers. Nutriband aims to submit an NDA for AVERSA Fentanyl to the FDA in Q1/Q2 2025, relying on a single phase 1 Human Abuse Potential study. If approved, AVERSA Fentanyl could be the first abuse-deterrent transdermal patch globally, with estimated peak annual sales of $80-$200 million. The company's total assets are valued at $13.63 million, with stockholders' equity at $12.5 million.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is hosting an exclusive live investor webinar and Q&A session on July 25, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature Chairman and President Serguei Melnik and CEO Gareth Sheridan discussing current operations and upcoming milestones.
Nutriband is focusing on addressing the global opioid crisis with its AVERSA™ abuse-deterrent transdermal technology. Their lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. The company is pursuing a streamlined 505(b)(2) NDA regulatory pathway, requiring only a single Phase 1 trial with potential for an expedited six-month FDA review.
Nutriband Inc. (NASDAQ:NTRB) has received a Notice of Allowance from the USPTO for its AVERSA™ trademark, a key component of its abuse-deterrent transdermal patch technology. The company's lead product, AVERSA™ Fentanyl, is progressing towards commercial manufacturing scale-up in partnership with Kindeva Drug Delivery. Nutriband plans to file an IND application with the FDA, preceding pivotal studies to demonstrate the abuse-deterrent properties of AVERSA™ Fentanyl.
The upcoming human abuse potential study will compare AVERSA™ Fentanyl to a current fentanyl patch without abuse-deterrent features. Preliminary studies indicate AVERSA™ technology's high resistance to manipulation. A market analysis projects potential peak annual U.S. sales of $80 million to $200 million for AVERSA™ Fentanyl, highlighting its significant market potential in abuse-deterrent pharmaceuticals.
Nutriband has provided an update on its Aversa Fentanyl product development program. The company, in collaboration with Kindeva Drug Delivery, has progressed in developing the commercial manufacturing process for a transdermal fentanyl patch incorporating Nutriband's AVERSA™ abuse-deterrent technology. This follows a feasibility agreement and a commercial development and clinical supply agreement between the two companies.
Kindeva has validated analytical methods for handling aversive agents required for the product. Nutriband plans to file an Investigational New Drug (IND) application with the FDA, including chemistry, manufacturing, and clinical study protocols for a Phase 1 human abuse potential study, which is pivotal for the New Drug Application (NDA) process. No Phase 2 or Phase 3 trials are needed.
The AVERSA Fentanyl patch aims to prevent drug misuse while ensuring accessibility for patients in need, with potential peak annual US sales estimated between $80 million to $200 million.
Nutriband reported Q1 revenues of $408,532, highlighting a 219% YoY increase in sports tape sales via its Pocono Pharma subsidiary. The company is leveraging penetration pricing to secure deals with major brands like KT Tape, Reebok, Adidas, and New Balance.
In Q1, Nutriband completed an $8.4M private placement at $4 per share, bringing its cash position to $8,347,739 as of April 30, 2024.
The company is advancing its AVERSA line, targeting a Q1 2025 NDA filing for AVERSA Fentanyl, projected to achieve peak annual sales of $80-$200M. AVERSA Buprenorphine could reach up to $130M in annual sales.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
How does Nutriband generate revenue?
What is the significance of Nutriband's intellectual property portfolio?
Who are Nutriband's strategic partners?
What problem does Nutriband aim to solve?
What is Nutriband's flagship product?
What industries does Nutriband operate in?
